Q2 FY2026 EarningsQ2 FY26 results beat consensus across all key financial metrics, with revenue of $26.9M exceeding the $26.0M expectation and GAAP EPS of -$0.71 significantly narrower than the -$0.90 consensus. Diagnostic Testing revenue grew 42% YoY, driving a gross margin beat of 82.0% vs. 79.9% expected. Management reaffirmed its full-year 2026 revenue guidance of $108-114M, indicating confidence in sustained 25% growth and a clear path toward Adjusted EBITDA profitability.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Biodesix(BDSX) the Revenue is 26.86 M (+34.18%), Beat estimate;the EBIT is -5.388 M (+44.56%), Beat estimate;the EPS is -0.71 (+55.63%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B34.18%
0.03B30.03%
+0.00B4.15%
EBITExceed expectations
-0.01B44.56%
-0.01B26.96%
+0.00B17.60%
EPSExceed expectations
-0.7155.63%
-0.902943.57%
+0.192912.06%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf